What's the Cheapest Legal Way to Get Your GLP-1? (Updated October 2026)
The cheapest legal way to get your GLP-1 depends on how you pay. If your commercial plan covers it, a stable copay (as low as $25/month with a manufacturer savings card) usually wins. On Medicare, the GLP-1 Bridge is $50/month if you qualify. Paying cash, self-pay starts at $149/month for the lowest pill doses. Pick your situation below.
Run your Price Check
Semaglutide (Wegovy) · Commercial insurance — covers GLP-1s
If your copay is stable, you don't need anything else — including us.
- Wegovy savings card (commercial insurance) $25/mo
as of Oct 25, 2026
The catch: Eligible commercial insurance only — Medicare, Medicaid and other government plans are excluded. Savings are capped at $100/month. Applies to both the Wegovy pen and the Wegovy pill.
View primary source ↗
You just checked this month's prices. Members get them re-checked every month with same-week alerts → GLP-1 Cost Tracker.
Every situation, side by side (October 2026)
The cheapest legal way to get a GLP-1 depends entirely on how you pay. If your commercial plan already covers it, a stable copay usually beats every workaround. If you're on Medicare, the GLP-1 Bridge is $50/month through December 31, 2027, if you qualify. If you're paying cash, manufacturer self-pay pricing is the real floor; Novo Nordisk's $0 patient-assistance program does not include Wegovy. Every price below carries an as-of date and a primary source.
| Situation | Medication | Cheapest verified option | Monthly price (as of) | The catch | Source |
|---|---|---|---|---|---|
| Commercial insurance — covers GLP-1s | Semaglutide (Wegovy) | Wegovy savings card (commercial insurance) | $25/mo (as of Oct 25, 2026) | Eligible commercial insurance only — Medicare, Medicaid and other government plans are excluded. Savings are capped at $100/month. Applies to both the Wegovy pen and the Wegovy pill. | Source ↗ |
| Commercial insurance — covers GLP-1s | Tirzepatide (Zepbound) | Zepbound savings card (commercial insurance) | $25/mo (as of Oct 25, 2026) | Commercial insurance only; applies to the single-dose pen (not the KwikPen or vials). Savings are capped at $100/month and $1,300/year, and the card expires 12/31/2026. | Source ↗ |
| Commercial insurance — covers GLP-1s | Foundayo (oral orforglipron) | Foundayo savings card (commercial insurance) | $25/mo (as of Oct 25, 2026) | Commercial insurance that covers Foundayo only; Medicare, Medicaid and other government plans are excluded. Savings are capped at $100/month and $1,000/year, and the card expires 12/31/2026. | Source ↗ |
| Commercial insurance — excludes GLP-1s | Semaglutide (Wegovy) | Wegovy self-pay (NovoCare) | $349/mo (0.25–2.4 mg pen) (as of Oct 25, 2026) | New patients pay $199/mo for the first 2 months (0.25 mg or 0.5 mg) through December 31, 2026, then $349/mo. The Wegovy HD 7.2 mg pen is $399/mo. The Wegovy pill is $149/mo (1.5 mg), $199/mo (4 mg), or $299/mo (9 mg and 25 mg). | Source ↗ |
| Commercial insurance — excludes GLP-1s | Tirzepatide (Zepbound) | Zepbound self-pay (LillyDirect) | $299–$449/mo (as of Oct 25, 2026) | Priced by dose, whether you get one KwikPen or four single-dose vials a month: $299 (2.5 mg), $399 (5 mg), or $449 (7.5 mg to 15 mg). The $449 price requires a refill within 45 days of your last delivery; otherwise you pay $499 (7.5 mg) or $699 (10 mg to 15 mg). Needles and other injection supplies are extra. | Source ↗ |
| Commercial insurance — excludes GLP-1s | Foundayo (oral orforglipron) | Foundayo self-pay (LillyDirect) | $149–$299/mo (as of Oct 25, 2026) | $149/mo for 0.8 mg and 2.5 mg, $199/mo for 5.5 mg, and $299/mo for 9 mg and up. The 2.5 mg and 5.5 mg prices are temporary through December 31, 2026 (regular $199 and $299). For 14.5 mg and 17.2 mg, the $299 price requires a refill within 45 days of your last delivery; otherwise it is $349/mo. | Source ↗ |
| Medicare | Semaglutide (Wegovy) | Medicare GLP-1 Bridge | $50/mo (as of Oct 25, 2026) | Covers the Wegovy pen and pill. You need a standalone Part D plan or a Medicare Advantage HMO or PPO plan with drug coverage, plus a prior authorization showing you meet CMS's BMI criteria. Not for people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH), or anyone getting a GLP-1 through Part D. Your Part D deductible does not apply, the $50 does not count toward your out-of-pocket cap, and Extra Help and coupons cannot lower it. Runs July 1, 2026 to December 31, 2027. | Source ↗ |
| Medicare | Tirzepatide (Zepbound) | Medicare GLP-1 Bridge | $50/mo (as of Oct 25, 2026) | Zepbound is covered as the KwikPen only, and pen needles are not covered. You need a standalone Part D plan or a Medicare Advantage HMO or PPO plan with drug coverage, plus a prior authorization showing you meet CMS's BMI criteria. Not for people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH), or anyone getting a GLP-1 through Part D. Your Part D deductible does not apply, the $50 does not count toward your out-of-pocket cap, and Extra Help and coupons cannot lower it. Runs July 1, 2026 to December 31, 2027. | Source ↗ |
| Medicare | Foundayo (oral orforglipron) | Medicare GLP-1 Bridge | $50/mo (as of Oct 25, 2026) | Covers all Foundayo doses. You need a standalone Part D plan or a Medicare Advantage HMO or PPO plan with drug coverage, plus a prior authorization showing you meet CMS's BMI criteria. Not for people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH), or anyone getting a GLP-1 through Part D. Your Part D deductible does not apply, the $50 does not count toward your out-of-pocket cap, and Extra Help and coupons cannot lower it. Runs July 1, 2026 to December 31, 2027. | Source ↗ |
| Medicaid | Semaglutide (Wegovy) | State Medicaid (where covered) | $0–low copay where covered; otherwise self-pay (Oct 25, 2026) | Coverage is state-by-state and, where offered, requires prior authorization and BMI criteria. KFF counted 13 state programs covering GLP-1s for weight loss in January 2026. Michigan narrowed its coverage on January 1, 2026. Since then, Massachusetts (July 1) and Rhode Island (October 1) have ended weight-loss coverage, and Utah limited its pilot approvals to June 30, 2026. | Source ↗ |
| Medicaid | Tirzepatide (Zepbound) | State Medicaid (where covered) | $0–low copay where covered; otherwise self-pay (Oct 25, 2026) | Coverage is state-by-state and, where offered, requires prior authorization and BMI criteria. KFF counted 13 state programs covering GLP-1s for weight loss in January 2026. Michigan narrowed its coverage on January 1, 2026. Since then, Massachusetts (July 1) and Rhode Island (October 1) have ended weight-loss coverage, and Utah limited its pilot approvals to June 30, 2026. | Source ↗ |
| Medicaid | Foundayo (oral orforglipron) | State Medicaid (where covered) | $0–low copay where covered; otherwise self-pay (Oct 25, 2026) | Coverage is state-by-state and, where offered, requires prior authorization and BMI criteria. KFF counted 13 state programs covering GLP-1s for weight loss in January 2026. Michigan narrowed its coverage on January 1, 2026. Since then, Massachusetts (July 1) and Rhode Island (October 1) have ended weight-loss coverage, and Utah limited its pilot approvals to June 30, 2026. | Source ↗ |
| Uninsured / paying cash | Semaglutide (Wegovy) | Wegovy self-pay (NovoCare) | $349/mo (0.25–2.4 mg pen) (as of Oct 25, 2026) | New patients pay $199/mo for the first 2 months (0.25 mg or 0.5 mg) through December 31, 2026, then $349/mo. The Wegovy HD 7.2 mg pen is $399/mo. The Wegovy pill is $149/mo (1.5 mg), $199/mo (4 mg), or $299/mo (9 mg and 25 mg). | Source ↗ |
| Uninsured / paying cash | Tirzepatide (Zepbound) | Zepbound self-pay (LillyDirect) | $299–$449/mo (as of Oct 25, 2026) | Priced by dose, whether you get one KwikPen or four single-dose vials a month: $299 (2.5 mg), $399 (5 mg), or $449 (7.5 mg to 15 mg). The $449 price requires a refill within 45 days of your last delivery; otherwise you pay $499 (7.5 mg) or $699 (10 mg to 15 mg). Needles and other injection supplies are extra. | Source ↗ |
| Uninsured / paying cash | Foundayo (oral orforglipron) | Foundayo self-pay (LillyDirect) | $149–$299/mo (as of Oct 25, 2026) | $149/mo for 0.8 mg and 2.5 mg, $199/mo for 5.5 mg, and $299/mo for 9 mg and up. The 2.5 mg and 5.5 mg prices are temporary through December 31, 2026 (regular $199 and $299). For 14.5 mg and 17.2 mg, the $299 price requires a refill within 45 days of your last delivery; otherwise it is $349/mo. | Source ↗ |
Frequently asked questions
- What is the cheapest legal way to get a GLP-1 in 2026?
- It depends on how you pay. If your commercial plan covers GLP-1s, a stable copay (as low as $25/month with a manufacturer savings card for Wegovy, Zepbound, or Foundayo) is usually the cheapest. On Medicare, the GLP-1 Bridge is $50/month through December 31, 2027, if you qualify. Paying cash, brand self-pay prices start at $149/month for oral Foundayo or the 1.5 mg Wegovy pill as of October 2026. Novo Nordisk's $0 patient-assistance program does not cover Wegovy.
- How much is Wegovy or Zepbound without insurance?
- As of October 25, 2026, the Wegovy pen is $349/month self-pay, or $199/month for the first two months for new patients through December 31, 2026. The Wegovy HD 7.2 mg pen is $399/month, and the Wegovy pill is $149 to $299/month by dose. Zepbound self-pay is $299 (2.5 mg), $399 (5 mg), or $449/month (7.5 mg to 15 mg) for a KwikPen or vials, but the $449 price requires a refill within 45 days or it rises to $499 to $699. TrumpRx.gov lists the same prices.
- What is the Medicare GLP-1 Bridge and who qualifies?
- The Medicare GLP-1 Bridge is a temporary CMS program that gives eligible Part D enrollees Wegovy (pen or pill), Zepbound (KwikPen only), or Foundayo for a flat $50/month copay when prescribed for weight management. It runs July 1, 2026 through December 31, 2027. You need a standalone Part D plan or a Medicare Advantage HMO or PPO plan with drug coverage, and your prescriber must get a prior authorization showing you meet CMS's BMI criteria. People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH), or who already get a GLP-1 through Part D, are not eligible. The $50 copay does not count toward your out-of-pocket cap, and coupons or Extra Help cannot lower it.
- Does Medicaid cover GLP-1s for weight loss?
- Only in some states. KFF counted 13 state Medicaid programs covering GLP-1s for obesity as of January 2026, usually with prior authorization and BMI criteria. California, New Hampshire, Pennsylvania, and South Carolina ended coverage on January 1, 2026, and Michigan limited it that day to people with severe obesity who have tried other treatments. Since then, Massachusetts (July 1, 2026) and Rhode Island (October 1, 2026) ended weight-loss coverage, and Utah limited its pilot approvals to June 30, 2026. Always confirm with your state's current Medicaid formulary.
- Can I use a manufacturer savings card if I have Medicare or Medicaid?
- No. Manufacturer savings cards for Wegovy, Zepbound, and Foundayo exclude government beneficiaries, including Medicare and Medicaid. Those programs have their own paths: the Medicare GLP-1 Bridge and state Medicaid coverage. You can still pay a manufacturer's self-pay price outside your insurance, but that spending does not count toward your Part D out-of-pocket costs.
- Is oral Foundayo cheaper than the injectable GLP-1s?
- At starting doses, yes, for cash-pay patients. As of October 25, 2026, Foundayo self-pay through LillyDirect is $149/month for 0.8 mg and 2.5 mg and $199/month for 5.5 mg (temporary prices through December 31, 2026; regular $199 and $299), then $299/month for 9 mg and up. The Wegovy pill also starts at $149/month (1.5 mg). Injectable self-pay starts at $199/month for Wegovy (first two months) and $299/month for Zepbound 2.5 mg. For Foundayo 14.5 mg and 17.2 mg, missing the 45-day refill window raises the price to $349/month.
All prices verified against their primary sources as of Oct 25, 2026. Every figure here is tracked in our monthly GLP-1 Price Index.